Stoke Therapeutics, Inc. announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company?s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his position as Stoke?s Chief Financial Officer effective May 7, 2024.

Mr. Leggett brings more than 20 years of experience as a biotechnology executive, board member and as an investment banker. He has led financial strategy and operations and secured financing for dozens of life science companies. Prior to joining Stoke, Mr. Leggett served as Chief Financial Officer at Affinia Therapeutics.

Before joining Affinia Therapeutics, Mr. Leggett was Chief Financial Officer at Black Diamond Therapeutics, where he led the Company?s $85 million Series C financing and $231 million IPO. Before joining Black Diamond, Mr. Leggett served as Chief Financial Officer at Axcella Health, where he helped raise $156 million across three financings, including an IPO. Mr. Leggett spent more than a decade as an investment banker for the healthcare groups at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities.

Mr. Leggett also currently serves on the board of directors of Clover Biopharmaceuticals Ltd. Mr. Leggett holds a Master of Business Administration in Finance from the Wharton School at the University of Pennsylvania and earned his Bachelor of Arts in Economics from Columbia University.